Betting that 
BMY will consolidate after crossing $46
**Bristol Myers Squibb (BMS)** has been busy advancing their pipeline, and they've got some intriguing developments. Imagine a bunch of scientists in lab coats doing a happy dance—I'm pretty sure that's happening at BMS right now. Here's the scoop:
1. **Doubling Down on Registrational Assets**: BMS plans to **double the number of registrational assets** over the next 18 months—from six to a whopping twelve! These are the heavy hitters—the ones that are marching toward regulatory approval. 🚀
2. **Cell Therapy Magic**: Brace yourself for some alphabet soup: They've got a CD19-directed **NEX T cell therapy** (that's like the Avengers of immune cells) called BMS-986353. It's not just a mouthful; it's also expanding into clinical trials for immunologic diseases, including severe, refractory systemic lupus erythematosus. Say that three times fast! 🌪️
3. **CAR T Awesomeness**: BMS is also cooking up a **potential first cell therapy** that targets GPRC5D. It goes by the snappy name **BMS-986393**. This little warrior is strapping on its armor and starting a registrational trial in relapsed/refractory multiple myeloma (RRMM). 🛡️
4. **BCMA x CD3 Tango**: Picture this: a dance floor, disco lights, and two partners—the BCMA protein and the CD3 T-cell. They're doing the tango, and it's called **alnuctumab**. This dynamic duo is advancing into a Phase 3 trial for—you guessed it—RRMM. 💃🕺
5. **Protein Degradation Drama**: BMS is introducing a potential game-changer: **golcadomide**, a first-in-class protein degrader. It's like the Marie Kondo of cancer treatment—tidying up large B-cell lymphoma. This one's moving into a Phase 3 trial, and I bet it's sparking joy in the lab. 🌿
6. **Androgen Receptor De-grabber**: Okay, that's not the official name, but close! BMS has an androgen receptor degrader (fancy science-speak for "let's dismantle this thing") that's strutting into pivotal studies in metastatic castration-resistant prostate cancer. 🕶️
So, in a nutshell, BMS is jazzed about their pipeline. They're like the Elon Musk of drug development—bold, ambitious, and ready to change lives. 🌎💙
Is there anything else you'd like to know? Maybe a fun fact about lab rats or the secret handshake of pharmaceutical CEOs? 😉
Source: Conversation with Copilot, 7/24/2024
(1) Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated .... news.bms.com/news/corporate-financial/2023/Bristol-Myers-Squibb-Highlights-Advancing-Pipeline-and-Differentiated-Research-Platforms-to-Support-Long-Term-Sustainable-Growth-at-RD-Day/default.aspx.
(2) Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated .... finance.yahoo.com/news/bristol-myers-squibb-highlights-advancing-123000365.html.
(3) Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated .... businesswire.com/news/home/20230914789335/en/Bristol-Myers-Squibb-Highlights-Advancing-Pipeline-and-Differentiated-Research-Platforms-to-Support-Long-Term-Sustainable-Growth-at-RD-Day.
(4) Bristol Myers Squibb - Bristol Myers Squibb Reports Fourth Quarter and .... news.bms.com/news/details/2024/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2023/default.aspx.
BMY will consolidate after crossing $46**Bristol Myers Squibb (BMS)** has been busy advancing their pipeline, and they've got some intriguing developments. Imagine a bunch of scientists in lab coats doing a happy dance—I'm pretty sure that's happening at BMS right now. Here's the scoop:
1. **Doubling Down on Registrational Assets**: BMS plans to **double the number of registrational assets** over the next 18 months—from six to a whopping twelve! These are the heavy hitters—the ones that are marching toward regulatory approval. 🚀
2. **Cell Therapy Magic**: Brace yourself for some alphabet soup: They've got a CD19-directed **NEX T cell therapy** (that's like the Avengers of immune cells) called BMS-986353. It's not just a mouthful; it's also expanding into clinical trials for immunologic diseases, including severe, refractory systemic lupus erythematosus. Say that three times fast! 🌪️
3. **CAR T Awesomeness**: BMS is also cooking up a **potential first cell therapy** that targets GPRC5D. It goes by the snappy name **BMS-986393**. This little warrior is strapping on its armor and starting a registrational trial in relapsed/refractory multiple myeloma (RRMM). 🛡️
4. **BCMA x CD3 Tango**: Picture this: a dance floor, disco lights, and two partners—the BCMA protein and the CD3 T-cell. They're doing the tango, and it's called **alnuctumab**. This dynamic duo is advancing into a Phase 3 trial for—you guessed it—RRMM. 💃🕺
5. **Protein Degradation Drama**: BMS is introducing a potential game-changer: **golcadomide**, a first-in-class protein degrader. It's like the Marie Kondo of cancer treatment—tidying up large B-cell lymphoma. This one's moving into a Phase 3 trial, and I bet it's sparking joy in the lab. 🌿
6. **Androgen Receptor De-grabber**: Okay, that's not the official name, but close! BMS has an androgen receptor degrader (fancy science-speak for "let's dismantle this thing") that's strutting into pivotal studies in metastatic castration-resistant prostate cancer. 🕶️
So, in a nutshell, BMS is jazzed about their pipeline. They're like the Elon Musk of drug development—bold, ambitious, and ready to change lives. 🌎💙
Is there anything else you'd like to know? Maybe a fun fact about lab rats or the secret handshake of pharmaceutical CEOs? 😉
Source: Conversation with Copilot, 7/24/2024
(1) Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated .... news.bms.com/news/corporate-financial/2023/Bristol-Myers-Squibb-Highlights-Advancing-Pipeline-and-Differentiated-Research-Platforms-to-Support-Long-Term-Sustainable-Growth-at-RD-Day/default.aspx.
(2) Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated .... finance.yahoo.com/news/bristol-myers-squibb-highlights-advancing-123000365.html.
(3) Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated .... businesswire.com/news/home/20230914789335/en/Bristol-Myers-Squibb-Highlights-Advancing-Pipeline-and-Differentiated-Research-Platforms-to-Support-Long-Term-Sustainable-Growth-at-RD-Day.
(4) Bristol Myers Squibb - Bristol Myers Squibb Reports Fourth Quarter and .... news.bms.com/news/details/2024/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2023/default.aspx.
Note
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.